Translating Regenerative Medicine to the Clinic

Erscheinungsjahr 2015
ISBN: 978-0-12-800548-4
Verlag: Elsevier Science

Buch, Englisch, 354 Seiten, Format (B × H): 211 mm x 277 mm, Gewicht: 1202 g

Translating Regenerative Medicine to the Clinic reviews the current methodological tools and experimental approaches used by leading translational researchers, discussing the uses of regenerative medicine for different disease treatment areas, including cardiovascular disease, muscle regeneration, and regeneration of the bone and skin.

Pedagogically, the book concentrates on the latest knowledge, laboratory techniques, and experimental approaches used by translational research leaders in this field. It promotes cross-disciplinary communication between the sub-specialties of medicine, but remains unified in theme by emphasizing recent innovations, critical barriers to progress, the new tools that are being used to overcome them, and specific areas of research that require additional study to advance the field as a whole.

Volumes in the series include Translating Gene Therapy to the Clinic, Translating Regenerative Medicine to the Clinic, Translating MicroRNAs to the Clinic, Translating Biomarkers to the Clinic, and Translating Epigenetics to the Clinic.

Zielgruppe

Translational researchers and clinicians

Autoren/Hrsg.

Laurence, Jeffrey

Baptista, Pedro

Atala, Anthony

Fachgebiete

• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Medizin, Gesundheitswesen Biomedizin, Medizinische Forschung, Klinische Studien

Inhaltsverzeichnis

Introduction: Regenerative Medicine for Cardiovascular Disease-A Good Start

PART I: STEM CELLS:

Chapter 1: Introduction and Overview of Stem Cells
Chapter 2: Mechanistic Insights from Pathologic Perspective

Chapter 3: Large Animal Models to Study Stem Cell Therapy
Section I. Body's Native Repair Mechanisms
Chapter 4. Evolution of understanding of the mechanisms of repair

Chapter 5: Impact of Age on Stem Cell Function
Section II: Autologous Bone Marrow
Chapter 6: Bone Marrow Mononuclear Cells
Chapter 7: Chronic Limb Ischemia
Chapter 8: Chronic/Refractory Angina
Chapter 9: Acute Myocardial Infarction
A. European Experience: Andreas Zeiher
B. US Experience: Jay Traverse

Chapter 10: Chronic Ischemic Heart Failure
Section III: Autologous Adipose Derived Regenerative Cells
Chapter 11: Adipose Tissue
Section IV: Allogeneic Alternatives to Autologous Bone Marrow
Chapter 12: Overview of MSCs

Chapter 13: Allogeneic vs Autologous Source: Comparative Effects
Chapter 14: Use of MSCs for AMI
Chapter 15: Combined Cell Strategies
Chapter 16: Heart Failure
Section V: Cardiac Progenitor Cells
Chapter 17: C-Kit+ cells
Chapter 18: Cardiospheres
Section VI: Other Allogeneic Sources of Stem Cells
Chapter 19: Umbilical Cord, Placenta, Endometrium
Section VII. Genetic Engineering/Cell Transformation
Chapter 20: Genetic Engineering of Fibroblasts to Cardiomyocytes
Chapter 21: Transformation to inducible Pleuripotent Stem Cells
Chapter 22: Transformation to MAPC's
Section VIII: METHODS OF DELIVERY:

Chapter 23. Transcoronary and Endocardial
Chapter 24. Retrograde and Epicardial
Part II. TISSUE ENGINEERING:

Chapter 25. Epicardial Patch
Chapter 26. Matrix Scaffolds
Chapter 27. Matrix plus cells
Chapter 28. Biomaterial
Chapter 29: Organogenesis
Part III. GENE THERAPY:

Chapter 30: Pre-clinical Identification of target genes
Chapter 31: SERCA-2a gene for recovery of inotropic function
Chapter 32: SDF-1 Gene for Heart Failure Non-Inotropic Mechanisms
Chapter 33: Gene Therapy for Angiogenesis: Chronic Limb Ischemia

Chapter 34: Stem Cells Target Gene Transfected Stem Cells
Part IV: FUTURE DIRECTIONS:

Chapter 35: CCTRN: Past, Present, and Vision for the Future
Chapter 36: Signature of Responders-lessons from Bio-Repository
Chapter 37: Adjunctive therapy with LVADs for Recovery
Chapter 38: Trials in Non-Ischemic Heart Failure

Chapter 39: Enhancing Stem Cell Homing for Tissue Repair
Chapter 40: Stroke: Pre-Clinical and Clinical Trial Data
SUMMARY

Über Autor(innen)

Baptista, Pedro
Pedro Baptista, PharmD, PhD, Marie Curie Alumni, is a Senior ARAID Researcher at IIS Aragon, Zaragoza, Spain, where he directs the Laboratory of Organ Bioengineering and Regenerative Medicine. He serves as a Visiting Professor of Biomedical Engineering at Universidad Carlos III de Madrid. Dr. Baptista earned his Pharmacy Degree from the University of Lisbon and completed his PhD training at the Wake Forest Institute for Regenerative Medicine in Winston-Salem, NC, USA. He is Secretary General of the European Society of Artificial Organs (ESAO) and Chair of the European Association for the Study of the Liver (EASL) Regenerative Hepatology Consortium. Dr. Baptista has published extensively in high-impact journals on organ bioengineering, organoids, and regenerative hepatology, holds four patents, and has successfully spun off several related technologies into companies.

Atala, Anthony
Anthony Atala, MD, is the G. Link Professor and Director of the Wake Forest Institute for Regenerative Medicine, and the W. Boyce Professor and Chair of Urology. Dr. Atala is a practicing surgeon and a researcher in the area of regenerative medicine. Fifteen applications of technologies developed in Dr. Atala's laboratory have been used clinically. He is Editor of 25 books and 3 journals. Dr. Atala has published over 800 journal articles and has received over 250 national and international patents. Dr. Atala was elected to the Institute of Medicine of the National Academies of Sciences, to the National Academy of Inventors as a Charter Fellow, and to the American Institute for Medical and Biological Engineering.

Dr. Atala has led or served several national professional and government committees, including the National Institutes of Health working group on Cells and Developmental Biology, the National Institutes of Health Bioengineering Consortium, and the National Cancer Institute's Advisory Board. He is a founding member of the Tissue Engineering Society, Regenerative Medicine Foundation, Regenerative Medicine Manufacturing Innovation Consortium, Regenerative Medicine Development Organization, and Regenerative Medicine Manufacturing Society.

Laurence, Jeffrey
Dr Laurence is pursuing the pathophysiology of cardiovascular and skeletal abnormalities linked to HIV disease and its therapies at Weill Cornell. Dr Laurence is the editor-in-chief of Translational Medicine, which Elsevier co-publishes with the CSCTR.